

# **Breast Cancer and the Hormone Receptor Model - A White Paper Monograph**

**Gary S. Donovitz, MD and Mandy Cotten, DNP**

## **Introduction**

In the United States, 240,000 women will develop breast cancer annually and 40,000 will succumb to the disease. Additionally, there are an estimated 63,960 cases of in-situ disease in the United States in 2018 (Seigel et al., 2018, National Cancer Institute, 2018).

We know that one of the greatest fears for women as their endogenous hormone production wanes and they explore the thought of requiring hormone replacement therapy is breast cancer (Walsh-Childers, Edwards & Grobmyer, 2011). Inadequate knowledge surrounding the effects of circulating hormone levels on breast cancer is fairly consistent throughout the medical community. At BioTE®, as we have surpassed 1 million pellet insertions, using both testosterone and/or estradiol hormones, the incidence of breast cancer in both pre-and post-menopausal women among our more than 3,500 providers remains remarkably low. Our experience invites one to ask the obvious question, can hormone optimization using subcutaneous hormone pellets reduce the incidence of breast cancer? If so, what is the likely mechanism for this? And finally, can testosterone pellet therapy be used safely and therapeutically in breast cancer survivors? In order to adequately be able to answer these questions, providers must understand several factors: screening, classification of breast cancer, and genetic markers that increase risk.

## **Screening**

Before we answer these questions, we need to review the screening recommendations and breast cancer classification. The United States Preventative Services Task Force reported in 2016 that they no longer recommend clinical breast exams, likewise the American Cancer Society in 2015 no longer recommends clinical breast exams. Mammogram recommendations vary from ACOG, USPTFS, and the American Cancer Society. In general, providers should be recommending mammograms starting by the age of 50 and continuing annually or biennially until the age of 75 if the patient is of average risk (National Cancer Institute, 2018, ACOG, 2017).

## **Breast Cancer Classification**

The classification of invasive breast cancer is important to understand before we overlay the hormone receptor theory and then apply the mechanism by which testosterone protects the breast tissue from cancer. Breast cancer is classified based on breast cancer type, grade, molecular subtypes, and stage (Onitilo et al., 2009). The type of breast cancer is based upon location and aggressiveness of the disease. Invasive breast cancer is a heterogeneous disease presenting most often as invasive ductal carcinoma in 75% of cases. Lobular

carcinoma, inflammatory carcinoma, and Paget's disease of the nipple occur less frequently (Onilio et al., 2009; Breastcancer.org, 2018).

The grade of the cancer is based upon how the tissue appears on biopsy and how fast the cells grow. Invasive ductal carcinoma has five molecular subtypes, and in general tends to be low grade, and less aggressive. Molecular subtypes are very important in determining the treatment plan and risk profile for the patient. The subtypes include luminal A, luminal B, triple negative/ basal like, HER2 (Human Epidermal Growth Factor Receptor 2) enriched, and normal like (Longo, Fauci, Kasper, Hauser, & Jameson, 2011, Breastcancer.org, 2018).

Luminal A has the highest level of estrogen receptor expression and are most likely to respond to endocrine therapy such as tamoxifen and aromatase inhibitors. In addition, this type of tumor is typically HER2 negative. The intracellular protein Ki-67, a protein identified with ongoing proliferation is low, and overall they have an favorable prognosis despite being less responsive to chemotherapy (Longo et al., 2011, Breastcancer.org, 2018).

In luminal B tumors, prognosis is worse than with Luminal A. Ki-67 protein is higher, consistent with increased proliferation. Hormone receptors are often positive and can also be HER2 receptor protein positive. Twenty percent of breast cancers have the gene mutation that makes excessive HER2 protein. Luminal B tumors subsequently grow faster than luminal A tumors. They often fail existing treatments and have lower 5- and 10-year survival (Longo et al., 2011, Breastcancer.org, 2018, Cheang et al., 2009).

The triple negative basal-like tumors account for 15-20% of all breast cancers and are devoid of estrogen, progesterone, and HER-2 receptors. They are more common in BRAC 1 gene mutated patients. These aggressive tumors respond better to chemotherapy and can have a binary response to androgens, which will be discussed further (Longo et al., 2011, Breastcancer.org, 2018).

HER2 enriched tumors account for 15 percent of breast cancers. They are estrogen and progesterone receptor negative, but HER2 positive. They are faster growing and more aggressive than their luminal tumor counterparts. These tumors frequently metastasize to the brain and unfortunately the anti-HER2 antibodies do not cross the blood brain barrier (Leylan-Jones et al., 2009). Treatment usually includes trastuzumab (Herceptin), which targets the HER2 protein (Perou et al., 2000).

Normal-like tumors are similar to luminal A disease: hormone-receptor, HER2 negative, and low levels of the protein Ki-67. These tumors have a good prognosis, but slightly worse than luminal A (Longo et al., 2011, Breastcancer.org, 2018).

### **BRCA1 and BRCA2 Mutations**

There are several genetic mutations that increase the risk of developing breast cancer. Probably the most well known and reported on are the mutations of the proteins BRCA1 and BRCA2. These proteins, like the metabolite 2-OH estrone, are involved in DNA repair. When either of these genes is mutated, or altered,

such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to cancer.

Women without the BRCA mutation have a 12% lifetime risk of developing breast cancer, and the average age for developing breast cancer in the BRCA (-) women is 61 years old (Howlander et al., 2018). With a mutation in the BRCA gene, the incidence of breast cancer increases to 60-80% and the average age of development decreases to 42 years old (Nathanson et al., 2001). Patients with BRCA 1 and BRCA 2 mutations also have a 20-40% chance of developing cancer in the same or contralateral breast in the years following diagnosis (Kuchenbaecker, Hopper, Barnes, et al., 2017 & Metcalfe et al., 2014).

The USPSTF recommends genetic screening for patients that have a significant family history such as: breast cancer diagnosis prior to age 50, cancer in bilateral breasts, family history of both breast and ovarian cancer, multiple family breast cancers, two or more primary BRCA1 or BRCA2 related cancers in same family member, male breast cancer, and Ashkenazi Jewish ethnicity (USPSTF, 2013). Breast cancers in patients with BRCA1 mutation tend to be triple negative.

A class of drugs called PARP (poly ADP ribose polymerase) inhibitors, which block the repair of DNA damage, have been found to help prevent the proliferation of cancer cells that have BRCA1 or BRCA2 mutations. Also, research has shown that prophylactic mastectomy and oophorectomy in these patients can increase their lifespan by up to 6 years (Grann et al., 1998).

### **Clinical Evidence, Breast Cancer, & the BioTE® Method**

Evidence supports the use of the BioTE® method of hormone optimization to reduce breast cancer. The risk of developing breast cancer has been shown to be increased by elevated endogenous estrogen levels (Henderson, 2000). In addition, androgens have been shown to counteract the proliferative effects of estrogen and progestogen in mammary tissue (Ando, 2002). Breast tissue extirpated from pre- and post-menopausal women also demonstrated the inhibitory effects of testosterone on breast cell proliferation (Hofling et al., 2007 & Dimitrakakis et al., 2003).

The corollary has also been reported that bio-available testosterone is significantly lower in women with breast cancer, which supports the protective role that hormone optimization with testosterone affords to patients (Dimitrakakis et al., 2010). Adherence to testosterone hormone pellet therapy has furthermore shown to reduce the incidence of breast cancer from 243 per 100,000 women years (placebo arm of the Women's Health Initiative) to 73 per 100,000 women years in the Dayton study in the subset of patients receiving testosterone or testosterone with anastrozole subcutaneous hormone pellet therapy (Glazer, 2013). At BioTE® using testosterone and/or testosterone and estradiol pellets in our observational prospective self-reporting study, the incidence of breast cancer was 56 per 100,000 women years after 9 years of follow-up. (In Press).

## Clinical Evidence & The Hormone Receptor Model

Now let's discuss the clinical evidence supporting the Hormone Receptor Model specifically targeting the Androgen Receptor. The benefits of testosterone optimization afore mentioned are both exciting and life-changing to women's healthcare. Even more exciting is the genesis of why this therapy reduces the incidence of breast cancer and why it has therapeutic implications for patients who are afflicted with the disease. A review of the history of androgen therapy reveals that testosterone and dihydrotestosterone were used successfully to treat breast cancer in the 1940's and 1950's (Hermann et al., 1946; Adair et al., 1946). Unfortunately, inaccurate dosing not individualized to the patient lead to masculinizing side effects. Now, decades later, the discovery of tamoxifen and aromatase inhibitors were thought to be better alternatives for the commercialization of breast cancer therapy with little thought being given to breast cancer prevention.

Over the past decade and a half, Dr. Ed Friedman has performed extensive research on the hormone receptor model which was published in 2013 (Friedman, 2013). The hormone receptor model is centered around the fact that endogenous serum estradiol levels are not the initiators of breast cancer but rather increased aromatase activity leading to high local levels of estradiol in epithelial cells and surrounding fat cells influence disease development. High levels of estradiol in the cells activate the ER alpha receptor increasing proliferation, lengthening chromosomal telomeres, and increasing BCL-2 protein leading to further accelerated proliferation of the cancer cells. In addition, the high levels of local estradiol increase 4-OH estrone, which is known to be mutagenic and causes DNA damage. Once the right mutation occurs the mutagenesis and proliferation cause excessive cell growth overtaking compensatory cell death. In other words, apoptosis is significantly reduced. In the past, HRT containing synthetic progestins accelerated this process by reducing the doubling time of tumors by 25% (Santen et al., 2012).

The hormone receptor model also helps to explain why progesterone may be harmful rather than protective in breast tumors occurring in patients with the BRCA mutated gene. Considering there are two progesterone receptors in breast tissue progesterone alpha and progesterone beta and their effect on proliferation is quite different. The normal breast cell has a predominance of progesterone beta receptors allowing for endogenous and exogenous progesterone to inhibit proliferation and reduce BCL2 protein, and thereby confer protection to the breast. In patients with the mutated BRCA gene there are almost no progesterone beta receptors. This occurrence allows for expression of progesterone alpha receptor which increases proliferation, telomere length, and BCL2 protein. BCL2 protein allows cancer cells to live longer and avoid apoptosis. Testosterone works by binding to the androgen receptor and downregulating the estrogen alpha receptor (Collins et al., 2011; Peters et al., 2009).

Surprisingly, the androgen receptor is the most widely expressed nuclear hormone receptor in the breast (Agrawal 2008). The intracellular androgen receptor is present in 77% of breast cancer tumors. In luminal A tumors, 91% have the androgen receptor, while it appears in 68% of luminal B tumors, and 59% expression in HER2 subtype tumors (Narayanan & Dalton, 2016, Dimitrakakis et al., 2004). Studies show an **inverse** relationship between tumors that possessed the androgen receptor and the size, grade, and lymph node status. On the contrary, tumors lacking an **intracellular androgen receptor** were mostly found to be grade 3 (fast growing, poorly differentiated cells).

The BioTE<sup>®</sup> Method of hormone optimization capitalizes on the tumoricidal effects of the activated androgen receptor. Most post-menopausal breast cancers are estrogen receptor positive and 75% of these tumors are androgen receptor positive allowing for us to increase apoptosis and decrease cellular proliferation. In addition, cancers with the androgen receptor expression have improved overall survival and disease-free survival (Vera-Badillo et al., 2014). Not only is the androgen receptor associated with smaller tumors, that are less aggressive, and lower grade, but also has been shown to be associated with lower risk of recurrence (Qu et al., 2013). The androgen receptor is also an excellent predictor of therapeutic response to tamoxifen. In patients who are androgen receptor negative, the response to tamoxifen is worse (Hilborn et al., 2016).

Now, we must discuss triple negative breast cancer. A study specifically looking at triple negative breast cancer and the androgen receptor, showed that the androgen receptor expression when present reduced recurrence and reduced the incidence of death (Agoff et al., 2003). In estrogen receptor negative (Er-), HER2 positive breast cancers, markers of proliferation like Ki-67 and carbonic anhydrase were lower if there were androgen receptors expressed, which was also associated with longer Disease-Free Survival (DFS) and Overall Survival (OS). Impressively, 59% of triple negative breast cancers are androgen receptor positive and therefore a target rich environment for testosterone optimization (Noh et al., 2014). Taking testosterone optimization and breast cancer therapy one step further, if the tumor cells have androgen synthesizing enzymes (i.e. capable of making testosterone and DHT intracellularly) and have androgen receptor expression, then proliferation markers as described above are **negatively** correlated and survival is shown to be better (McNamara et al., 2013).

One should also consider the intracrine androgen synthesis which occurs in breast cancer cells. Higher intracellular androgen concentrations in estrogen receptor positive tumors are strongly associated with better prognosis and a more favorable OS and DFS (Choi, 2015). What is not discussed in this article but is thought-provoking, is the **membrane androgen receptor** which is completely different from the intracellular androgen receptor. The membrane androgen receptor increases pro-apoptotic proteins and decreases BCL2 protein accelerating cell death in breast cancer cells. This is the essence of the hormone receptor model postulated by Ed Friedman, PhD (2013).

Although, the majority of studies portend the benefits of the androgen receptor in the prognosis of breast cancer, there have been a few studies whereby there was a decrease in disease free survival (DFS). This most notably occurs in triple negative breast cancers and may be the result of a mutated gene leading to a mutated androgen receptor (Lehmann, 2014). In these somewhat more limited cases, an androgen antagonist is a better choice for therapeutic intervention.

### Conclusion

In conclusion, it appears that the fears of developing breast cancer with usage of hormone replacement therapy could potentially be prevented by proper hormone optimization especially with the inclusion of testosterone. For those women whose lives have been compromised by breast cancer, hormone optimization with testosterone may not only improve their quality of life but also may be the therapeutic answer to improving their overall survival and defeating the cancer.

## References

- Adair, F. & Herrmann, J. (1946). The use of testosterone propionate in the treatment of advanced carcinoma of the breast. *Ann Surg*, 123, 1023-35.
- Agoff, S., Swanson, P., Linden, H., Hawes, S., & Lawton, T. (2003). Androgen receptor expression in estrogen receptor-negative breast cancer. *Am J Clin Pathol*, 120, 725-31.
- Agrawal A., Jelen M., Grzelenek Z., et al. Androgen Receptor as a prognostic and predictive factor in breast cancer. *Folia Histochem Cytobio* 2008; 46: 269-76.
- American College of Obstetricians and Gynecologists (2017). ACOG Practice Bulletin: Breast cancer risk assessment and screening in average risk women. Retrieved from <https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Bulletins/Committee-on-Practice-Bulletins-Gynecology/Breast-Cancer-Risk-Assessment-and-Screening-in-Average-Risk-Women>.
- Ando, S., De Amicis, F., Rago, V., Carpino, A., Maggiolini, M., Panno, M., & Lanzino, M. (2002). Breast cancer from estrogen to androgen receptor. *Mol Cell Endocrinology*, 19, 121-128.
- Breastcancer.org. (2018). Types of breast cancer. Retrieved from <https://www.breastcancer.org/symptoms/types>.
- Cheang, M., Chia, S., Voduc, D., Gao, D., Leung, S., Snider, J., et al. (2009). Ki67 index, HER2 status, and prognosis in patients with luminal B breast cancer. *J. Natl. Cancer Inst.* 101, 736-750.
- Choi, J., Kang, S., Lee, S., & Bae, Y. (2015). Androgen receptor expression predicts decrease survival in early stage TNBC. *Ann Surg Oncol*, 22(1), 82-89.
- Collins, L., Cole, K., Marotti, J., Hu, R., Schnitt, S., & Tamimi, R. (2011). Androgen receptor in breast cancer in relation to the molecular phenotype. *Mod Pathol* 2011;24:924-31
- Dimitrakakis, C., Zhou, J., & Wang, J. (2003). A physiologic role for testosterone limiting estrogenic stimulation of the breast. *Menopause*, 10, 292-8.
- Dimitrakakis, C., Jones, R., Liu, A., & Bondy, C. (2004). Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. *Menopause*, 11, 531-5
- Dimitrakakis, C., Zava, D., Marinopoulos, S., Tsigginou, A., Antsaklis, A., & Glaser, R. (2010). Low salivary testosterone levels in patients with breast cancer. *BMC Cancer*, 10, 547.
- Friedman E. (2013). *The New Testosterone Treatment*. Prometheus Books.
- Glazer R. (2013). Reduced breast cancer incidence in women treated with subcutaneous testosterone. *Maturitas*, 76, 342-349.
- Grann, V, Panageas, K., Whang, W, et al. (1998). Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. *J Clin Oncol*, 16(3), 979-985.
- Henderson, B. (2000). Hormonal Carcinogenesis. *Carcinogenesis*, 21(3), 427-33.
- Herrmann, J. & Adair, F. (1946). The effects of testosterone propionate on carcinoma of the female breast with soft tissue metastasis. *J Clin Endocrin Metab*, 6, 769-775.

Hilborn E. (2016). Androgen receptor expression predicts beneficial tamoxifen response. *Br J Cancer*, 114, 248-55.

Hofling, M, Hirschberg, A, Skoog, L, et al.(2007). Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. *Menopause*, 14, 183.

Howlander, N., Noone, A., Krapcho, M., Miller, D., Bishop, K., Kosary, C., et al. (2018). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, [https://seer.cancer.gov/csr/1975\\_2014/](https://seer.cancer.gov/csr/1975_2014/), based on November 2016 SEER data submission.

Kuchenbaecker, K., Hopper, J., Barnes, D., et al. (2017). Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *JAMA*, 317(23), 2402-2416.

Lehmann, B., Bauer, J., Schafer, J., Pendleton, C., Tang, L., Johnson, K. et al. (2014). PIK3CA mutations in androgen receptor positive triple negative breast cancer confers sensitivity to the combination of PI3K and androgen receptor inhibitors. *Breast Cancer Res*.

Leylan-Jones, B. (2009). Human Epidermal growth factor receptor 2 positive breast cancers and CNS metastasis. *J Clin Oncol*, 27, 5278-86.

Longo, D., Fauci, A., Kasper, D., Hauser, S., & Jameson, J. (2011). *Harrison's Principles of Internal Medicine* (18<sup>th</sup> Ed.) McGraw Hill.

McNamara KM, Yoda, T, Miki, Y, Chanplakorn, N., Wongwaisayawan, S., Incharoen, P et al. (2013). Androgen pathway in triple negative invasive ductal tumors. *Cancer Sci*, 104, 639-46.

Metcalf, K, Gershman, S, Ghadirian, P, Lynch, H, Snyder, C, Tung, N, et al. (2014). Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. *BMJ*, 348.

(PDF) The Manchester guidelines for contralateral risk-reducing mastectomy. Available from: [https://www.researchgate.net/publication/280911207\\_The\\_Manchester\\_guidelines\\_for\\_contralateral\\_risk-reducing\\_mastectomy](https://www.researchgate.net/publication/280911207_The_Manchester_guidelines_for_contralateral_risk-reducing_mastectomy) [accessed Dec 10 2018].

Narayanan, R. & Dalton T. (2016). Androgen Receptor: A complex therapeutic target for breast cancer. *Cancers*, 8, 108-25.

Nathanson, K. (2015). Breast Cancer genetics. *Natural Medicine*, 7, 552-56.

National Cancer Institute (2018). *Breast cancer treatment*. Retrieved from <https://www.cancer.gov/types/breast/hp/breast-treatment-pdq>.

Noh S., Kim, J., & Koo, J. (2014). Metabolic differences in estrogen receptor negative breast cancer is based on androgen receptor status. *Tumor Biol*, 35, 8179-92.

Onitilo, A., Engel, J., Greenlee, R., & Mukesh, B. (2009). Breast cancer subtypes based on ER/PR and HER2 expression. *Clin Med Res*, 7, 4-13.

Perou, C., Sorlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C., et al. (2000). Molecular portraits of human breast tumors. *Nature*, 407, 748-52.

Peters, A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M., Harris, J. et al. (2009). Androgen receptor inhibits estrogen receptor - alpha activity and is prognostic in breast cancer. *Cancer Res*, 69, 6131-40.

- Qu, Q., Mao, Y., Fei, X., & Shen, K. (2013). The impact of the androgen receptor expression on breast cancer survival. *Plos One*, 8:e82650
- Santen R., Uyue, W., & Heitan, D. (2012). Modeling of the growth kinetics of occult breast tumors. *Cancer Epidemiology, Biomarkers and Prevention*, 21(7), 1038-48.
- Siegel, R., Miller, K., & Jemal, A. (2018). Cancer Statistics, 2018. *CA Cancer Journal Clin*, 68(1), 7-30.
- U.S. Preventative Services Task Force (USPSTF) (2013). Breast cancer risk assessment, genetic counseling, & genetic testing. Retrieved from <https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing>.
- Vera-Badillo FE, Templeton, A., deGouveia, P, Diaz-Padilla, I, Bedard, P., Al-Mubarak, M. et al. (2014). androgen receptor expression and outcomes in early breast cancer. *J Natl Cancer Inst*
- Walsh-Childers, K., Edwards, H., & Grobmyer, S. (2011). Covering women's greatest health fear: Breast cancer information in consumer magazines. *Health Communication*, 26:3, 1-12.